SLC5A2 and chronic kidney disease: In an animal model of chronic kidney disease and anthracycline-induced cardiomyopathy, SGLT2 inhibitors were found to reduce oxidative stress by inhibiting NADPH oxidase 1 and 2 as well as the PI3K/Akt signaling pathway while lowering levels of oxidized proteins.